Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
4 hedge funds and large institutions have $4.51M invested in Plus Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0% less capital invested
Capital invested by funds: $4.53M → $4.51M (-$18.8K)
22% less call options, than puts
Call options by funds: $36K | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$617K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$309K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$617K |
| 2 |
Goldman Sachs
New York
|
-$27K |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $213 | – | – | – |
|
|
27
Goldman Sachs
New York
| – | -$27K | – | – |
|
|
28
Wolverine Trading
Chicago,
Illinois
| – | -$21K | – | – |
|
PSTV Hedge Fund Activity: Q1 2017 in Review
4 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2017, worth a combined $4.51M — down 0.41% from $4.53M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PSTV positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $617K. The largest seller was Sabby Management, cutting an estimated $617K.
- 4 institutional investors held Plus Therapeutics (PSTV) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $4.51M of Plus Therapeutics stock for Q1 2017, down 0.41% quarter-over-quarter.
- 1 fund opened new Plus Therapeutics positions in Q1 2017 and 0 closed out, a net change of +1 holder.
- The largest Plus Therapeutics buyer in Q1 2017 was BlackRock, an estimated $617K added.
- The largest Plus Therapeutics seller in Q1 2017 was Sabby Management, an estimated $617K sold.
Based on aggregated 13F filings for Q1 2017.